Bone building with bortezomib

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

In this issue of the JCI, Mukherjee et al. report that bortezomib, a clinically available proteasome inhibitor active against myeloma, induces the differentiation of mesenchymal stem/progenitor cells (MSCs) - rather than mature osteoprogenitor cells - into osteoblasts, resulting in new bone formation (see the related article beginning on page 491). These results were observed when MSCs were implanted subcutaneously in mice or were used to treat a mouse model of postmenopausal bone loss. Others have reported that immunomodulatory drugs (e.g., thalidomide and lenalidomide), which are active against myeloma, also block the activity of bone-resorbing osteoclasts. These results reflect the utility of targeting endogenous MSCs for the purpose of tissue repair and suggest that combining different classes of agents that are antineoplastic and also inhibit bone destruction and increase bone formation should be very beneficial for myeloma patients suffering from severe bone disease.

Original languageEnglish (US)
Pages (from-to)462-464
Number of pages3
JournalJournal of Clinical Investigation
Volume118
Issue number2
DOIs
StatePublished - Feb 1 2008
Externally publishedYes

Fingerprint

Mesenchymal Stromal Cells
Bone and Bones
Osteogenesis
Postmenopausal Osteoporosis
Proteasome Inhibitors
Thalidomide
Bone Diseases
Osteoclasts
Osteoblasts
Antineoplastic Agents
Bortezomib
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bone building with bortezomib. / Roodman, G. David.

In: Journal of Clinical Investigation, Vol. 118, No. 2, 01.02.2008, p. 462-464.

Research output: Contribution to journalArticle

@article{200a6882e8c74e5a87e342d116bd8bf0,
title = "Bone building with bortezomib",
abstract = "In this issue of the JCI, Mukherjee et al. report that bortezomib, a clinically available proteasome inhibitor active against myeloma, induces the differentiation of mesenchymal stem/progenitor cells (MSCs) - rather than mature osteoprogenitor cells - into osteoblasts, resulting in new bone formation (see the related article beginning on page 491). These results were observed when MSCs were implanted subcutaneously in mice or were used to treat a mouse model of postmenopausal bone loss. Others have reported that immunomodulatory drugs (e.g., thalidomide and lenalidomide), which are active against myeloma, also block the activity of bone-resorbing osteoclasts. These results reflect the utility of targeting endogenous MSCs for the purpose of tissue repair and suggest that combining different classes of agents that are antineoplastic and also inhibit bone destruction and increase bone formation should be very beneficial for myeloma patients suffering from severe bone disease.",
author = "Roodman, {G. David}",
year = "2008",
month = "2",
day = "1",
doi = "10.1172/JCI34734",
language = "English (US)",
volume = "118",
pages = "462--464",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Bone building with bortezomib

AU - Roodman, G. David

PY - 2008/2/1

Y1 - 2008/2/1

N2 - In this issue of the JCI, Mukherjee et al. report that bortezomib, a clinically available proteasome inhibitor active against myeloma, induces the differentiation of mesenchymal stem/progenitor cells (MSCs) - rather than mature osteoprogenitor cells - into osteoblasts, resulting in new bone formation (see the related article beginning on page 491). These results were observed when MSCs were implanted subcutaneously in mice or were used to treat a mouse model of postmenopausal bone loss. Others have reported that immunomodulatory drugs (e.g., thalidomide and lenalidomide), which are active against myeloma, also block the activity of bone-resorbing osteoclasts. These results reflect the utility of targeting endogenous MSCs for the purpose of tissue repair and suggest that combining different classes of agents that are antineoplastic and also inhibit bone destruction and increase bone formation should be very beneficial for myeloma patients suffering from severe bone disease.

AB - In this issue of the JCI, Mukherjee et al. report that bortezomib, a clinically available proteasome inhibitor active against myeloma, induces the differentiation of mesenchymal stem/progenitor cells (MSCs) - rather than mature osteoprogenitor cells - into osteoblasts, resulting in new bone formation (see the related article beginning on page 491). These results were observed when MSCs were implanted subcutaneously in mice or were used to treat a mouse model of postmenopausal bone loss. Others have reported that immunomodulatory drugs (e.g., thalidomide and lenalidomide), which are active against myeloma, also block the activity of bone-resorbing osteoclasts. These results reflect the utility of targeting endogenous MSCs for the purpose of tissue repair and suggest that combining different classes of agents that are antineoplastic and also inhibit bone destruction and increase bone formation should be very beneficial for myeloma patients suffering from severe bone disease.

UR - http://www.scopus.com/inward/record.url?scp=38849159333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849159333&partnerID=8YFLogxK

U2 - 10.1172/JCI34734

DO - 10.1172/JCI34734

M3 - Article

C2 - 18219395

AN - SCOPUS:38849159333

VL - 118

SP - 462

EP - 464

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -